Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock-option grants to four non-executive employees totaling 20,800 options, approved May 1, 2026 under the 2018 Equity Inducement Plan.

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock-option grants to four non-executive employees totaling 20,800 options, approved May 1, 2026 under the 2018 Equity Inducement Plan.

The options carry a 10-year term, an exercise price of $69.42 (Nasdaq close May 1, 2026) and a standard 1/4 then monthly vesting schedule.

Argus May 4 session

-0.42% close to close Open Argus

Details

News Market Reaction – SYRE

In the May 4 session, SYRE declined 0.42%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine employee equity inducement awards covering 20,800 options at an ex...

Analysis

This announcement details routine employee equity inducement awards covering 20,800 options at an exercise price of $69.42, granted under Spyre’s 2018 plan and aligned with Nasdaq Listing Rule 5635(c)(4). In context, Spyre recently raised over $400M and reported strong SPY001 Phase 2 data while maintaining about $741M in cash and securities. Investors may watch future use of the $500M shelf and additional trial updates as more material catalysts than these grants.

Key Figures

Inducement options granted: 20,800 shares Option exercise price: $69.42 Current share price: $69.42 +5 more

Inducement options granted

20,800 shares

Stock options to four non-executive employees under 2018 Equity Inducement Plan

Option exercise price

$69.42

Exercise price equal to SYRE Nasdaq closing price on May 1, 2026

Current share price

$69.42

Latest price in market context, up 3.56% over last 24 hours

Market capitalization

$5,919,979,740

Equity value based on latest share price

Shelf registration size

$500,000,000

Maximum aggregate offering under February 19, 2026 Form S-3 shelf

Cash & securities

$741,000,000

Preliminary cash, cash equivalents and marketable securities as of March 31, 2026

Public offering size

$403,000,000

Total public offering price for 6,500,000 shares at $62.00 (April 15, 2026 424B5)

Offering gross proceeds

$463,500,000

Gross proceeds from offering including 975,000-share over-allotment (April 16, 2026 8-K)

Historical Context

5 past events · Latest: Apr 16

5 events

1. Apr 16

   Equity offering close

   24h Move

   +4.8%

   Closed $463.5M public offering including full over-allotment exercise.

2. Apr 14

   Equity offering pricing

   24h Move

   +7.8%

   Priced upsized $403.0M common stock offering at $62.00 per share.

3. Apr 13

   Equity offering proposed

   24h Move

   +1.2%

   Announced proposed $300.0M offering with additional underwriter option.

4. Apr 13

   Phase 2 data update

   24h Move

   +23.4%

   Reported SPY001 SKYLINE Part A met primary and key secondary endpoints.

5. Apr 10

   Results call announcement

   24h Move

   +23.4%

   Set date and call details to report SPY001 Part A topline results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, nasdaq listing rule 5635(c)(4), stock options

3 terms

equity inducement awards financial

"to four non-executive employees as equity inducement awards under the Spyre"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"approved the grant of stock options to purchase an aggregate of 20,800 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on May 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $69.42, the closing price per share of Spyre's common stock as reported by Nasdaq on May 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Spyre Therapeutics (SYRE) announce on May 1, 2026 regarding inducement awards?

Spyre granted an aggregate of 20,800 stock options to four non-executive employees. According to the company, the grants were approved May 1, 2026 under the 2018 Equity Inducement Plan with a 10-year term and $69.42 exercise price.

What is the exercise price and term for the SYRE inducement stock options?

The options carry an exercise price of $69.42 and a 10-year term. According to the company, the $69.42 price equals Spyre's Nasdaq closing price on May 1, 2026 and the options expire ten years from grant.

How do the Spyre (SYRE) options vest for the new employees?

Vesting is one-fourth of shares after the first anniversary, then one-forty-eighth monthly thereafter. According to the company, vesting is subject to continuous service through each applicable vesting date.

Why were the stock options granted as inducement awards under Nasdaq rules for SYRE?

The options were material to each employee's acceptance of employment and granted under Nasdaq Listing Rule 5635(c)(4). According to the company, that rule permits equity inducements for new hires approved by an independent compensation committee.

Are the SYRE inducement options subject to any plan terms or conditions?

Yes, the options are subject to the terms of Spyre's 2018 Equity Inducement Plan as amended. According to the company, all grants follow the plan's provisions, including exercise, vesting and forfeiture conditions.